Additionally, if youre living with obesity and struggling to lose weight, GLP-1s effectively support clinically significant weight loss of more than 10% of body weight
In a pre- and postnatal development study in pregnant cynomolgus monkeys, subcutaneous doses of 0.015, 0.075 and 0.15 mg/kg twice weekly (1.3-, 6.4- and 14-fold the MRHD) were administered from Gestation Day 16 to 140
Staying within the broader abdominal zone but well clear of the navel gives you a large, consistent target area with good medication uptake
Ongoing medical follow-up helps manage dosing and side effects
In patients with obesity, GLP-1RAs were not associated with a significantly increased risk of intestinal obstruction in patients with T2DM and obesity when compared to other anti-diabetic medications, except for insulin (Fig
Need to know if injectable GHK-Cu can be mixed with TB-500 in the same syringe